Inozyme price target lowered to $23 from $30 at Piper Sandler

Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Inozyme (INZY) to $23 from $30 and keeps an Overweight rating on the shares following transfer in coverage as the firm views it as “a diamond in the rough.” Indeed, while shares are down about 75% in the last 12 months, Inozyme has continued to execute, Piper says. With sightlines to ‘701’s first approval in a largely untapped market plus strategic reprioritization which extends cash runway to Q1 2026, the firm thinks the risk/reward here is positive and remains Overweight rated.